Literature DB >> 20483755

Synoviocyte innate immune responses: II. Pivotal role of IFN regulatory factor 3.

Susan E Sweeney1, Trevor B Kimbler, Gary S Firestein.   

Abstract

Innate immune responses contribute to synovial inflammation in rheumatoid arthritis. The present study was designed to investigate the contribution of IFN regulatory factor (IRF)3 and IRF7 to type I IFN-regulated gene expression in synoviocytes. Fibroblast-like synoviocytes were stimulated with polyinosinic-polycytidylic acid (poly [I-C]) after transfection with IRF3 or IRF7 small interfering RNA to knockdown transcription factor expression. Western blots, luciferase assay after transfection with reporter constructs, quantitative PCR, and AP-1 DNA binding ELISA were performed to evaluate the role of IRF3 and IRF7 in poly (I-C)-induced signaling and synoviocyte gene expression. IRF3 regulates IFN-stimulated response element (ISRE) promoter activity as well as IFN-beta, IRF5, IRF7, RANTES, IFN-inducible protein-10, MCP-1, and MIP1alpha gene expression in response to poly (I-C). IRF7 knockdown modestly decreased a subset of genes and ISRE activity, although the results were not statistically significant. Surprisingly, IRF3 knockdown almost completely blocked expression of additional genes in which the ISRE is not traditionally considered a dominant promoter site in fibroblast-like synoviocytes, including matrix metalloproteinase (MMP)3, MMP9, IL-6, and IL-8. Transcription factor activation studies demonstrated a role for IRF3 in regulation of c-Jun phosphorylation and AP-1 binding. IRF3 rather than IRF7 regulates poly (I-C)-induced type I IFN responses in human synoviocytes by increasing ISRE promoter activity. IRF3 also partially regulates expression of other cytokines and MMP through activation of c-Jun and the AP-1 promoter site. Targeting synoviocyte IRF3 represents a potential approach to suppress diverse mediators while limiting suppression of IRF7-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483755      PMCID: PMC2913682          DOI: 10.4049/jimmunol.0903944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Triggering the interferon antiviral response through an IKK-related pathway.

Authors:  Sonia Sharma; Benjamin R tenOever; Nathalie Grandvaux; Guo-Ping Zhou; Rongtuan Lin; John Hiscott
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

2.  Antiviral gene expression in rheumatoid arthritis: role of IKKepsilon and interferon regulatory factor 3.

Authors:  Susan E Sweeney; Ling Mo; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2007-03

3.  The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.

Authors:  T J Smeets; J M Dayer; M C Kraan; J Versendaal; R Chicheportiche; F C Breedveld; P P Tak
Journal:  Arthritis Rheum       Date:  2000-02

4.  Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.

Authors:  Deepa R Hammaker; David L Boyle; Martine Chabaud-Riou; Gary S Firestein
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

5.  Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis.

Authors:  Snaevar Sigurdsson; Leonid Padyukov; Fina A S Kurreeman; Ulrika Liljedahl; Ann-Christin Wiman; Lars Alfredsson; René Toes; Johan Rönnelid; Lars Klareskog; Tom W J Huizinga; Gunnar Alm; Ann-Christine Syvänen; Lars Rönnblom
Journal:  Arthritis Rheum       Date:  2007-07

6.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

7.  Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis.

Authors:  Rebeca Dieguez-Gonzalez; Manuel Calaza; Eva Perez-Pampin; Arturo Rodriguez de la Serna; Benjamin Fernandez-Gutierrez; Santos Castañeda; Raquel Largo; Beatriz Joven; Javier Narvaez; Federico Navarro; Jose Luis Marenco; Jose Luis Vicario; Francisco J Blanco; Jesus Carlos Fernandez-Lopez; Rafael Caliz; María Dolores Collado-Escobar; Luis Carreño; Javier Lopez-Longo; Juan D Cañete; Juan J Gomez-Reino; Antonio Gonzalez
Journal:  Arthritis Rheum       Date:  2008-05

8.  Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.

Authors:  M Corr; D L Boyle; L Ronacher; N Flores; G S Firestein
Journal:  Ann Rheum Dis       Date:  2008-07-24       Impact factor: 19.103

9.  Quantitative biomarker analysis of synovial gene expression by real-time PCR.

Authors:  David L Boyle; Sanna Rosengren; William Bugbee; Arthur Kavanaugh; Gary S Firestein
Journal:  Arthritis Res Ther       Date:  2003-10-08       Impact factor: 5.156

Review 10.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

View more
  17 in total

1.  Role of interferon regulatory factor 7 in serum-transfer arthritis: regulation of interferon-β production.

Authors:  Susan E Sweeney; Maripat Corr; Trevor B Kimbler
Journal:  Arthritis Rheum       Date:  2011-11-10

2.  IRF3 polymorphisms induce different innate anti-Theiler's virus immune responses in RAW264.7 macrophages.

Authors:  Tyler C Moore; Fahd M Al-Salleeh; Deborah M Brown; Thomas M Petro
Journal:  Virology       Date:  2011-08-02       Impact factor: 3.616

3.  NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus.

Authors:  Magali Audry; Michael Ciancanelli; Kun Yang; Aurelie Cobat; Huey-Hsuan Chang; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Tim Niehues; Janine Reichenbach; Xiao-Xia Li; Alain Israel; Laurent Abel; Jean-Laurent Casanova; Shen-Ying Zhang; Emmanuelle Jouanguy; Anne Puel
Journal:  J Allergy Clin Immunol       Date:  2011-07-01       Impact factor: 10.793

4.  Significant role for IRF3 in both T cell and APC effector functions during T cell responses.

Authors:  Zacharey Guinn; Anna T Lampe; Deborah M Brown; Thomas M Petro
Journal:  Cell Immunol       Date:  2016-09-04       Impact factor: 4.868

Review 5.  Interferon regulatory factor signaling in autoimmune disease.

Authors:  Bharati Matta; Su Song; Dan Li; Betsy J Barnes
Journal:  Cytokine       Date:  2017-03-07       Impact factor: 3.861

6.  Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.

Authors:  Chiara Angiolilli; Aleksander M Grabiec; Bradley S Ferguson; Caroline Ospelt; Beatriz Malvar Fernandez; Inge E van Es; Lisa G M van Baarsen; Steffen Gay; Timothy A McKinsey; Paul P Tak; Dominique L Baeten; Kris A Reedquist
Journal:  Ann Rheum Dis       Date:  2014-12-01       Impact factor: 19.103

7.  Activation of IRF3 contributes to IFN-γ and ISG54 expression during the immune responses to B16F10 tumor growth.

Authors:  Zachary Guinn; Deborah M Brown; Thomas M Petro
Journal:  Int Immunopharmacol       Date:  2017-06-23       Impact factor: 4.932

8.  Targeting interferon regulatory factors to inhibit activation of the type I IFN response: implications for treatment of autoimmune disorders.

Authors:  Susan E Sweeney
Journal:  Cell Immunol       Date:  2011-08-10       Impact factor: 4.868

9.  Lipopolysaccharide potentiates polychlorinated biphenyl-induced disruption of the blood-brain barrier via TLR4/IRF-3 signaling.

Authors:  Jeong June Choi; Yean Jung Choi; Lei Chen; Bei Zhang; Sung Yong Eum; Maria T Abreu; Michal Toborek
Journal:  Toxicology       Date:  2012-08-13       Impact factor: 4.221

10.  IRF3 and ERK MAP-kinases control nitric oxide production from macrophages in response to poly-I:C.

Authors:  Tyler C Moore; Thomas M Petro
Journal:  FEBS Lett       Date:  2013-07-23       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.